Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06436326
Other study ID # 202311035RINC
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date June 30, 2026

Study information

Verified date January 2024
Source National Taiwan University Hospital
Contact HUNG-HUI CHEN, PhD
Phone 886-2-2394-7109
Email hunghuichen@ntu.edu.tw
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).


Description:

Background: The global prevalence of gestational diabetes mellitus is increasing. To reduce the negative impact of gestational diabetes mellitus on maternal and fetal health, managing blood glucose during pregnancy is important, which also shows the importance of blood glucose monitoring. Continuous glucose monitoring (CGM) is different from traditional blood glucose meters (BGM). Continuous glucose monitoring is now known to have good control effects in type 1 and type 2 diabetes mellitus. However, there are still few randomized controlled trials for gestational diabetes mellitus and there are not consistent results. In addition, blood glucose management conditions vary among groups with different dietary habits, socioeconomic status and income. Food culture of Taiwan is diverse and it is easy to consume sugar or high carbohydrate foods. Continuous glucose monitoring can be more sensitive to measure glucose fluctuations, but it is still unknown whether it will have different maternal and infant health effects for groups whose glucose is prone to exceed the target range. Objective: To explore the impact of continuous glucose monitoring on the health outcomes of mothers and infants with gestational diabetes mellitus, and to test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income) on the relationship between continuous glucose monitoring and the health outcomes among mothers with gestational diabetes mellitus and their infants. Methods: This study was a randomized controlled trial. It was expected that 120 pregnant women with gestational diabetes mellitus would be randomly assigned to the " Control group" (40 people) using blood glucose meters (BGM), or the "experimental group" (80 people) using continuous glucose monitoring (CGM) at a ratio of 1:2. In the "experimental group", they would be assigned to the " Experimental group1-Continuous glucose monitoring (CGM) group" (40 people) or the " Experimental group2-Continuous glucose monitoring (CGM) with nursing care group" (40 people). The " Experimental group2-Continuous glucose monitoring (CGM) with nursing care group " would provide nursing intervention during the perinatal period. The outcome variables of the three groups would be tracked and compared with 3 time points, which were 24 to 32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4 to 12 weeks after delivery. The primary outcomes were maternal glycemic parameters, cardiometabolic risk factors, and fetal macrosomia. Secondary outcomes included gestational weight, depression and infant growth curve.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date June 30, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged 18 years or above - Pregnant women diagnosed with gestational diabetes mellitus - Those who are willing to participate in this study Exclusion Criteria: - Those who have been diagnosed with diabetes mellitus "before pregnancy" - Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.) - Those who is with abnormal coagulation function

Study Design


Intervention

Device:
Continuous glucose monitor
Participants will receive a set of continuous glucose monitor (CGM) at "24-32 weeks of pregnancy (first set)" and "33 weeks of pregnancy to before delivery (second set)," respectively. CGM wearing instruction will be provided before the first wearing at "24-32 weeks of pregnancy". After completing the first wearing (approximately 14 days after starting to wear), the investigators will provide a glucose monitor report. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor report was given approximately 14 days after starting to wear.
Behavioral:
Perinatal nursing care for gestational diabetes
Individual nursing care and consultation for pregnant women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support.
Other:
Blood glucose meters (BGM)
Participants are required to use blood glucose meters (BGM) at "24-32 weeks of pregnancy" and "33 weeks to before delivery". After 14 days of glucose monitoring at "24-32 weeks of pregnancy", a glucose monitor report will be given to the participants. After the 14 days of glucose monitoring at "33 weeks to before delivery ", another glucose monitor report will be given to the participants.

Locations

Country Name City State
Taiwan National Taiwan University Hospital Hsin-Chu Branch BioMedical Park Hospital Hsinchu

Sponsors (1)

Lead Sponsor Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal Oral glucose tolerance test Oral glucose tolerance test (OGTT) including fasting, 1-hour, and 2-hour glucose levels. 24-32 weeks of pregnancy, 4-12 weeks postpartum
Primary Maternal glycated albumin glycated albumin 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Maternal albumin albumin 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Maternal fasting plasma glucose fasting plasma glucose 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Maternal insulin insulin 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Total cholesterol total cholesterol 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Triglycerides triglycerides 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary High-density lipoprotein high-density lipoprotein 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Low-density lipoprotein low-density lipoprotein 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Primary Fetal macrosomia Fetal macrosomia is defined as a birth weight =4,000 g. 4-12 weeks postpartum
Secondary Gestational weight gain Gestational weight gain will be based on pre-pregnancy Body Mass Index (BMI) and classified according to the Institute of Medicine (IOM) recommendations. 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery
Secondary Depression Edinburgh Postnatal Depression Scale (EPDS) The EPDS is a 10-item questionnaire. Each item scores from 0-3. The total score is found by adding together the scores for each of the 10 items. The minimum is 0 and the maximum is 30. Scoring above 12 or 13 are likely to be suffering from depression. 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Infant growth curve infant growth curve 4-12 weeks postpartum
Secondary Maternal average fasting plasma glucose average fasting plasma glucose 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Maternal average plasma glucose, Post-cibum average plasma glucose, Post-cibum 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Postpartum weight retention the weight change from pre-pregnancy to a period postpartum 4-12 weeks postpartum
Secondary Insulin medications dosage and insulin form 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Hypertensive disorders in pregnancy Number of Participants with preeclampsia-eclampsia or gestational hypertension 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery
Secondary Cesarean Section Number of Participants with Cesarean Section 4-12 weeks postpartum
Secondary Exercise Frequency Number of exercises per week. 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Health behavior change of glycemic control Scale A 3-item Likert scale based on the Transtheoretical model, including self-monitoring of glucose level, diet and physical activity. Each item scores from 0-4. A higher score means closer to the action or maintenance stage. 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Health Belief of glycemic control Scale A 21-item Likert scale based on the Health Belief model includes 5 categories: perceived susceptibility, perceived severity, perceived benefits, perceived barriers and self-efficacy.
Each item scores from 0-4. A higher score means higher the individual's beliefs about preventing diseases or maintaining health in perceived susceptibility, perceived severity, perceived benefits and self-efficacy categories. A higher score means higher the individual's barriers to preventing diseases or maintaining health in the perceived barriers category.
24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Quality of life assessment World Health Organization Quality-of-Life Scale:BREF Taiwan Version The scale evaluates four domains of quality of life ("Physical Health," "Psychological Health," "Social Relationships," and "Environment"), and contains four other questions :overall perception of quality of life, general health, dietary ,feel respected. Every domain scores from 4-20. Higher scores mean a better quality of life. 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, 4-12 weeks postpartum
Secondary Glucose monitoring satisfaction Scale Satisfaction of using continuous glucose monitoring (CGM) or blood glucose meters (BGM) access by Likert scale. A 4-item Likert scale includes 4 categories: ease of use, painful, convenience and overall satisfaction. Each item scores from 1-5. A higher score means lower satisfaction. 33 weeks of pregnancy to before delivery
Secondary Perceived benefits and barriers of CGM Benefits of CGM (BenCGM) and Burdens of CGM (BurCGM) Questionnaires. A 16-item Likert scale includes 2 categories: benefits of CGM and burdens of CGM. Each item scores from 1-5. A higher score means a higher benefit in benefit of CGM category. A higher score means higher burdens in burdens of CGM category. 33 weeks of pregnancy to before delivery
See also
  Status Clinical Trial Phase
Recruiting NCT06099574 - A Study on the Oral Health Status of Pregnant Women With Gestational Diabetes and Its Correlation With Oral Flora
Completed NCT02744300 - Balance After Baby Intervention for Women With Recent Gestational Diabetes N/A
Completed NCT02890693 - Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus and Their Offspring N/A
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Completed NCT02436551 - Gestational Diabetes in Central Asia: Prevalence and Management
Recruiting NCT02275845 - Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus Phase 3
Recruiting NCT04621396 - The Next Generation Longitudinal Birth Cohort Diabetes Study
Completed NCT01931280 - A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring N/A
Completed NCT01916694 - Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus N/A
Not yet recruiting NCT01637727 - Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women N/A
Completed NCT01565564 - Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes N/A
Recruiting NCT00550979 - Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk N/A
Completed NCT00460018 - Diet, Exercise, and Breastfeeding Intervention Program for Women With Gestational Diabetes (DEBI Trial) Phase 2
Not yet recruiting NCT04915716 - Effect of Fasting Time Before Cesarean Section on Neonatal Blood Glucose in Pregnant Women With Gestational Diabetes Mellitus
Completed NCT04422821 - Flash Glucose Monitoring in Gestational Diabetes Mellitus: Study Protocol for a Randomized Controlled Trial N/A
Recruiting NCT04369313 - Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers N/A
Recruiting NCT05348863 - SPARK- a Digital Platform to Improve Self-management of Gestational Diabetes N/A
Recruiting NCT04272840 - The Impact of Glycemic Index Education on Lowering Dietary GI in Gestational Diabetes Mellitus N/A
Completed NCT02588729 - A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT N/A
Completed NCT01922791 - Nutrition and Pregnancy Intervention Study N/A